Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 31, 2020
Daily News
July 31, 2020
- NCC, BrightPath Identify Peptide Vaccine Candidates for COVID-19
July 31, 2020
- Ono Drops ONO-5334 for COVID-19, Pursues Foipan Project
July 31, 2020
- Teva Takeda Deal Aimed at Boosting Efficiency, Quality: Nichi-Iko Chief
July 31, 2020
- Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
- Nichi-Iko Pulls Out from Avigan Contract Manufacturing
July 31, 2020
- 28 Products from 10-Plus Firms Recalled due to Flawed Tests at Kyowa CritiCare
July 31, 2020
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Eisai Seeks Lenvima’s Label Expansion into Thymic Carcinoma
July 31, 2020
- PMDA Provided Preliminary Info on MID-NET Use for Free in “Just Under 10 Cases”: Official
July 31, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…